Solid forms of a promoter of spinogenesis

Crystalline 2-(2-(2-(2-(4-(benzo[d]thiazol-2-yl)phenoxy)ethoxy)ethoxy)ethoxy)ethan-1-ol (Compound I Form II) characterized by an X-ray powder diffractogram comprising the following peaks (°2θ±0.2 °2θ):

• about 9.2, about 13.8, and about 16.1, as determined on a diffractometer using Cu-Kα radiation at a wavelength of 1.5406 Å.

Crystalline 2-(2-(2-(2-(4-(benzo[d]thiazol-2-yl)phenoxy)ethoxy)ethoxy)ethoxy)ethan-1-ol (Compound I Form III) characterized by an X-ray powder diffractogram comprising the following peaks (°2θ±0.2 °2θ):

• about 7.7, about 10.3, and about 15.3, as determined on a diffractometer using Cu-Kα radiation at a wavelength of 1.5406 Å.

Crystalline 2-(2-(2-(2-(4-(benzo[d]thiazol-2-yl)phenoxy)ethoxy)ethoxy)ethoxy)ethan-1-ol (Compound I Form IV) characterized by an X-ray powder diffractogram comprising the following peaks (°2θ±0.2 °2θ):

• about 5.4, about 22.4, and about 23.3, as determined on a diffractometer using Cu-Kα radiation at a wavelength of 1.5406 Å.

Crystalline 2-(2-(2-(2-(4-(benzo[d]thiazol-2-yl)phenoxy)ethoxy)ethoxy)ethoxy)ethan-1-ol (Compound I Form V) characterized by an X-ray powder diffractogram comprising the following peaks (°2θ±0.2 °2θ):

• about 4.6, about 9.2, and about 23.1, as determined on a diffractometer using Cu-Kα radiation at a wavelength of 1.5406 Å.

A pharmaceutical composition comprising one or more crystalline forms of any of the preceding claims and one or more pharmaceutically acceptable carriers.

A process for preparing Compound I, or a pharmaceutically acceptable salt thereof:

• comprising contacting Compound A with Compound B to form Compound I:
• under first reaction conditions comprising a halide.